Aeglea Bio Therapeutics (NASDAQ: AGLE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.
Valuation & Earnings
This table compares Aeglea Bio Therapeutics and Ultragenyx Pharmaceutical’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aeglea Bio Therapeutics||$5.20 million||33.99||-$27.23 million||($1.80)||-5.87|
|Ultragenyx Pharmaceutical||$2.61 million||966.92||-$302.13 million||($7.11)||-7.15|
Aeglea Bio Therapeutics has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Aeglea Bio Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Aeglea Bio Therapeutics and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeglea Bio Therapeutics||-523.37%||-48.29%||-44.47%|
Volatility & Risk
Aeglea Bio Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
Insider & Institutional Ownership
47.4% of Aeglea Bio Therapeutics shares are owned by institutional investors. Comparatively, 87.2% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 27.0% of Aeglea Bio Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for Aeglea Bio Therapeutics and Ultragenyx Pharmaceutical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeglea Bio Therapeutics||0||0||2||0||3.00|
Aeglea Bio Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 41.91%. Ultragenyx Pharmaceutical has a consensus target price of $68.94, suggesting a potential upside of 35.52%. Given Aeglea Bio Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Aeglea Bio Therapeutics is more favorable than Ultragenyx Pharmaceutical.
Aeglea Bio Therapeutics beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.